Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 113INDUSTRY 90NIH 14NETWORK 7OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

fludarabine 7Cyclophosphamide 7Nivolumab 6Metformin 4pembrolizumab 3fludarabine phosphate 3Radiotherapy 3Melphalan 3Ipilimumab 3Interleukin-2 3Injections 3S 1 (combination) 2Irinotecan 2tremelimumab 1selinexor 1parsaclisib 1olaparib 1nabiximols 1ivarmacitinib 1durvalumab 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1carfilzomib 1apatorsen 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Topotecan 1Rituximab 1Radiosurgery 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER_GOV × Dexamethasone × Clear all
NCT04813653 2025-07-24

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Tel-Aviv Sourasky Medical Center

Phase 1 Completed
3 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡